

August 1, 2024

[REDACTED]
Administrator
Parker Personal Care, Inc.
103 Seward Street
Parker, Pennsylvania 16049

RE: Parker Personal Care
License #: 426560

Dear [REDACTED]:

Thank you for your request for a waiver of 55 Pa. Code § 2600 (relating to personal care homes). You have requested to waive 55 Pa. Code § 2600.190(b) (relating to medication administration training) to allow unlicensed direct care staff to administer subcutaneous injections of GLP-1 agonist medications.

2600.190 Medication Administration Training

(b) A staff person is permitted to administer insulin injections following successful completion of a Department-approved medications administration course that includes the passing of a written performance-based competency test within the past 2 years, as well as successful completion of a Department-approved diabetes patient education program within the past 12 months.

1. Each direct care staff person who will administer subcutaneous injections of GLP-1 agonist medications must successfully complete and pass the Department of Human Services's medication administration course; receive in-person training on administering subcutaneous injections from a licensed health care professional and receive training on the specific medication being administered, including potential side effects, medication interactions, and appropriate observation and reporting from a licensed health care professional.
2. Each direct care staff person who will administer subcutaneous injections of GLP-1 agonist medications must have four hours of annual training related to GLP-1 agonist medications, and diabetes management.

3. Not all annual training must be conducted at the same time. The Department recommends spreading training out throughout the training year.

Up to three of the four required annual training hours may be comprised of actual training hours received in Diabetes education, as required by §2600.190(b) and §2800.190(b).

Up to one of the four required annual training hours may be comprised of skills demonstrations and/or observation of subcutaneous injection of GLP-1 agonist medication administration conducted by a Certified Diabetes Educator or a licensed health care professional that is employed by the facility or under contract for consultation.

Up to one of the four required annual training hours may be comprised of self-guided training, web-modules, or videos.

4. The initial training required by this waiver fulfills the requirements for annual training during the training year in which this waiver was issued. For subsequent training years, the annual training requirements must be met within your facility's predetermined training year.
5. The home must utilize a process for monitoring, evaluating, and documenting the administration of subcutaneous injection of the GLP-1 agonist medications.
6. A policy regarding the administration of subcutaneous injection of GLP-1 agonist medications including written procedures for administration, documentation, monitoring, evaluating, observation, and reporting must be developed and provided to all direct care staff who will administer these medications as part of their training.
7. The facility must have a clinical contact available at all times to answer any questions regarding the administration of subcutaneous injection of GLP-1 agonist medications. The clinical contact must be an employee of the facility or under contract.

Sincerely,



Theresa Hartman, RN, CCM
Bureau Director, Human Services Licensing
Office of Long-Term Living
Department of Human Services